BioSpace News Archive

Gilead Sciences’ Kite Pharma has entered into a collaboration and licensing agreement with biotech startup Appia Bio, which will focus on the joint research and development of allogeneic cell therapies for cancer.

A United Kingdom watchdog organization has accused Pfizer and Flynn Pharma of violating antitrust rules and overcharging that country’s National Health Services for anti-epilepsy treatments.

Legal firms are lining up to lead litigation against the company on behalf of shareholders who saw their stock dive.

Asia Green Biotechnology Corp. announced that it has secured an agreement with a director of the Company to complete two separate financing transactions for the purpose of addressing certain expenses tied to ongoing and possible new research activities being conducted or which may be commenced by the Company pursuant to the terms of its technology licensing agreements with InPlanta Biotechnology Ltd., Pathway RX Inc.

ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, reported financial results for the quarter ended June 30, 2021 and provided a business update.

Valneva SE, a specialty vaccine company focused on the development and commercialization of prophylactic vaccines for infectious diseases with significant unmet medical need, announced positive topline results from the Phase 3 pivotal trial of its single-shot chikungunya vaccine candidate, VLA1553.

Addex Therapeutics, a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, reported its half-year and second quarter financial results for the periods ended June 30, 2021 and provided a corporate update.

Everest Medicines announced that the Center for Drug Evaluation of the National Medical Products Administration of the People’s Republic of China has approved a Clinical Trial Application for XeravaTM for the treatment of community-acquired bacterial pneumonia.

Vifor Pharma Group reported profitable revenue growth in H1 supported by a strong recovery in Ferinject® / Injectafer® with sales up 22.8% at CER as a result of improved patient access as COVID-19 restrictions eased in key markets.

Noema Pharma, a Swiss-based clinical stage company targeting orphan central nervous system diseases, announces the initiation of its first clinical trial, a Phase 2a dose ranging study of the PDE10A inhibitor NOE-105 in Tourette Syndrome.